Douglas C Palmer - National Cancer Institute;National Institutes of Health;National Cancer Institute, National Institutes of Health

基本信息

Career Trajectory

Bio

I am devoted to innovating and translating novel immunotherapies for the treatment of metastatic cancer. At the NCI, I spent over 19 years working for Immunotherapy pioneers Nick Restifo and Steven Rosenberg trying to uncover the fundamentals of Immuno-Oncology. Now as the Executive Director of Immuno-Oncology at AstraZeneca under the tutelage of Cancer Biology guru Carl Barrett, I am making immunotherapies for cancer patients a reality.

Research Interests

Papers共 114 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Initial TCR Signal Strength Imprints GATA3 and Tbet Expression Driving T-helper Cell Fate Decisions

Mohammad Ameen Al-Aghbar, Taushif Khan,Meritxell Espino Guarch,Douglas C Palmer,Nicholas van Panhuys

biorxiv（2024）

Cited0Views0Bibtex

Supplementary Figure 2 from Determinants of Successful CD8+ T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice

Christopher A. Klebanoff,Luca Gattinoni,Douglas C. Palmer,Pawel Muranski, Yun Ji,Christian S. Hinrichs,Zachary A. Borman,Sid P. Kerkar,Christopher D. Scott,Steven E. Finkelstein,Steven A. Rosenberg,Nicholas P. Restifo

openalex（2023）

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn